PAH Space Getting Hotter as Actelion Files Macitentan NDA
LONDON – There's a race to market for a new generation of pulmonary arterial hypertension (PAH) drugs with Actelion Ltd. announcing it has filed for FDA approval of Opsumit (macitentan) and Bayer Healthcare revealing positive Phase III data for riociguat and promising global filings in the first half of 2013.
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST